Core Viewpoint - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has re-submitted its prospectus after a previous lapse, with Guojin Securities (Hong Kong) as its sole sponsor. The company focuses on developing biopharmaceuticals for allergic and autoimmune diseases but has reported continuous losses since its establishment in 2020 [1][2]. Financial Performance - Tianchen Biopharmaceuticals reported losses of RMB 95.78 million, RMB 137.32 million, and RMB 137.57 million for the years ending December 31, 2023, and 2024, and for the nine months ending September 30, 2025, respectively, totaling approximately RMB 370 million in cumulative losses over two years and nine months [2][4]. - The company’s revenue for 2023 was RMB 2.33 million, with research and development costs amounting to RMB 73.91 million, leading to a pre-tax loss of RMB 95.78 million [3][4]. Cash Flow and Financing - The net cash flow used in operating activities was RMB 60.87 million for 2023, RMB 104.12 million for 2024, and RMB 90.79 million for the nine months ending September 30, 2025, indicating a trend of negative cash flow [5]. - The company may require additional financing to support its growth plans due to negative operating cash flow, which could lead to increased costs and potential liquidity issues if sufficient external funding is not secured [6]. Supply Chain Risks - The company faces risks related to supplier concentration, with the top five suppliers accounting for 48.58%, 51.65%, and 43.21% of total purchases in 2023, 2024, and the nine months ending September 30, 2025, respectively. This reliance may expose the company to price increases or supply shortages [6].

Group 1 - The core viewpoint of the article is that Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Guotai Junan Securities (Hong Kong) as the exclusive sponsor [1] - Tianchen Biopharmaceuticals is focused on the development of innovative drugs, specifically targeting allergic and autoimmune diseases [1] - The company has established a comprehensive pipeline of biopharmaceutical products aimed at various medical fields, including otolaryngology, dermatology, respiratory medicine, hematology, nephrology, and other autoimmune diseases [1]

Group 1 - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. submitted its Hong Kong IPO application on August 21, 2025, which will expire on February 21, 2026, with Guotai Junan Securities (Hong Kong) as the sole sponsor [1] - The company focuses on the development of innovative drugs, particularly in the clinical stage, targeting allergic and autoimmune diseases through self-discovery and development of biopharmaceuticals [2] - Tianchen Biopharmaceuticals has established a comprehensive pipeline of biopharmaceutical products aimed at various medical fields, including otolaryngology, dermatology, respiratory medicine, hematology, nephrology, and other autoimmune diseases [2] Group 2 - The company is positioned to leverage its expertise in innovative drug development, two self-developed technology platforms (high-affinity antibody discovery platform and bispecific antibody development platform), and strong R&D capabilities to create innovative drugs for allergic and autoimmune diseases [2]

Group 1 - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. submitted its Hong Kong IPO application on August 21, 2025, which will expire on February 21, 2026, with Guotai Junan Securities (Hong Kong) as the sole sponsor [1] - The company focuses on the development of innovative drugs, specifically targeting allergic and autoimmune diseases, and has established a comprehensive pipeline of biopharmaceutical products across various medical fields [2] - Tianchen Biopharmaceuticals aims to leverage its expertise in innovative drug development, two self-developed technology platforms (high-affinity antibody discovery platform and bispecific antibody development platform), and strong R&D capabilities to create innovative drugs for allergic and autoimmune diseases [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Tianchen Biopharma to provide supplementary information regarding its overseas listing application, focusing on fundraising estimates and shareholder transparency [1][2] Group 1: Regulatory Requirements - CSRC requires Tianchen Biopharma to clarify the expected fundraising amount after the full exercise of the over-allotment option [1][2] - The company must disclose the situation regarding its shareholders, specifically OFC Bohui Fund and OFC Jiazi Fund, after upward penetration [1] - Legal opinions are required to confirm the company's compliance with foreign investment policies and necessary qualifications for its business operations [1] Group 2: Company Overview - Tianchen Biopharma is a clinical-stage biopharmaceutical company focused on the development of innovative drugs for allergic and autoimmune diseases [2] - The company has established a comprehensive pipeline of biopharmaceutical products targeting various medical fields, including otolaryngology, dermatology, respiratory, hematology, nephrology, and other autoimmune diseases [2] - The growth of the global and Chinese markets for autoimmune and allergic diseases supports Tianchen Biopharma's ongoing reliance on its expertise in innovative drug development and strong R&D capabilities [2]

Core Viewpoint - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has submitted its listing application, focusing on the development of biopharmaceuticals for allergic and autoimmune diseases, with significant financial losses reported since its establishment in 2020 [1][2]. Financial Performance - Tianchen Biopharmaceuticals has not generated any revenue since its inception, reporting losses of RMB 95.778 million, RMB 137.321 million, and RMB 94.208 million for the years 2023, 2024, and the first half of 2025, respectively, totaling approximately RMB 327 million over two and a half years [1][2]. - The company anticipates continued losses due to increased R&D investments and enhanced sales and marketing activities [2]. Cash Flow and Financing - The net cash flow from operating activities has shown a negative trend, with outflows of RMB 60.865 million, RMB 104.122 million, and RMB 47.673 million for the years 2023, 2024, and the first half of 2025, respectively [3][4]. - As of June 30, 2025, the company had cash and cash equivalents amounting to RMB 136.118 million, with financial assets valued at RMB 155 million [3]. Supply Chain Concentration - The company has a moderately concentrated supply chain, with purchases from the top five suppliers accounting for 48.58%, 51.65%, and 57.93% of total procurement for the years 2023, 2024, and the first half of 2025, respectively [4][5]. - Although this concentration is not deemed significantly high, the company is actively implementing strategies to mitigate potential risks, including diversifying supply bases and closely monitoring supplier performance [5].